Minoxidil
| Minoxidil | |
|---|---|
| Salts [] | |
|---|---|
| Minoxidil tartrate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 209.25 g/mol [1] |
| Melting point | 248 °C [1] |
| Solubility | 2200 mg/L [1] |
| Predicted LogP | 1.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C9H15N5O |
| IUPAC name | 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine |
| SMILES | C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O |
| InChI | InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2 |
| InChIKey | ZIMGGGWCDYVHOY-UHFFFAOYSA-N |
| CAS number | 38304-91-5 |
| UNII | 5965120SH1 |
| PubChem CID | 4201 |
| Pharmacokinetics[] | |
|---|---|
| Onset | Oral: 30–60 minutes (peak), Sublingual: 30 minutes |
| Elimination half-life | Oral: 3–4 hours, Topical: 22 hours[3] |
| Duration of action | Oral: ~72 hours, Topical: 10–12 hours |
| Metabolism | Primarily liver via glucuronidation, hydroxylation, and sulfation (SULT1A1, SULT2A1) |
| Excretion | Urine: >97% (10–15% unchanged; within 12–20 hours for oral and 4 days for topical) |
| Routes of administration | Oral, sublingual, topical (solution, foam, spray) |
Minoxidil (also known as Loniten, Rogaine, Minoximen, Theroxidil, Alopexil, Alostil, Tricoxidil, Lonolox, Regaine or Normoxidil) is a calcium channel blocker substance of the piperidine class.
Chemistry
Salts []
Stereochemistry []
Minoxidil is achiral.
Druglikeness
Lipinski's rule of five
Minoxidil matches Lipinski's rule of five.Pharmacology
ATC Classification
- (D11AX01)
Mechanism of action []
Minoxidil is thought to promote the survival of human dermal papillary cells (DPCs) or hair cells by activating both extracellular signal-regulated kinase (ERK) and Akt and by preventing cell death by increasing the ratio of BCl<sup>-</sup>2/Bax. Minoxidil may stimulate the growth of human hairs by prolonging anagen through these proliferative and anti-apoptotic effects on DPCs. Minoxidil, when used as a vasodilator, acts by opening adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells. This vasodilation may also improve the viability of hair cells or hair follicles. [1]
Interactions []
Medical side effects []
38 side effects listed on drug labels in SIDER 4.1 (minoxidil).
- Angina pectoris
- Breast disorder
- Cardiac tamponade
- Oedema
- Toxic epidermal necrolysis
- Dermatitis
- Rash
- Gastrointestinal disorder
- Cardiac disorder
- Hypertrichosis
- Hypotension
- Leukopenia
- Mediastinal disorder
- Nausea
- Pericardial effusion
- Pericarditis
- Pleural effusion
- Erythema multiforme
- Stevens-Johnson syndrome
- Tachycardia
- Thrombocytopenia
- Virilism
- Vomiting
- Weight increased
- Oedema peripheral
- Dermatitis bullous
- Bullous eruption
- Blood alkaline phosphatase increased
- Malnutrition
- Skin disorder
- Hair growth abnormal
- Breast tenderness
- Fluid retention
- Water retention
- Electrocardiogram ST segment
- Hair colour changes
- Electrocardiogram abnormal
- Blood creatinine increased
Indications
- Cardiac output increased
- Encephalopathy
- Hypertension
- Refractory hypertension
- Retinal disorder
- Vascular resistance systemic
- Water retention
Subjective effects []
| 0xea / Minoxidil [] | |
|---|---|
Routes:
| |
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4201, Minoxidil. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4201
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Minoxidil. UNII: 5965120SH1. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5965120SH1
Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. The Journal of Dermatological Treatment. June 2022; 33(4):1896–1906. PMID 34159872. https://doi.org/10.1080/09546634.2021.1945527
59445 WOMEN'S REGAINE EXTRA STRENGTH Minoxidil 5% application bottle. Therapeutic Goods Administration (TGA) / Australian Government Department of Health and Aged Care. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=59445&agid=%28PrintDetailsPublic%29&actionid=1
Search the TGA website. Tga-search.clients.funnelback.com. https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=79914
Loniten Tablets 5mg - Summary of Product Characteristics (SmPC). Medicines.org.uk. November 24, 2020. https://www.medicines.org.uk/emc/product/4296/smpc
Regaine for Men Extra Strength Scalp Foam 5% w/w Cutaneous Foam (GSL) - Summary of Product Characteristics (SmPC). (emc). April 27, 2021. https://www.medicines.org.uk/emc/product/5781/smpc
Regaine for Women Once a Day Scalp Foam 5% w/w Cutaneous Foam - Summary of Product Characteristics (SmPC). Medicines.org.uk. October 28, 2020. https://www.medicines.org.uk/emc/product/5082/smpc
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 10:20:29 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 10:20:25 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 10:20:25 |
| gsrs | ok | 2026-11-20 10:20:26 |
| hmdb | missing (no HMDB id) | 2026-11-20 10:20:25 |
| kegg | ok | 2026-11-20 10:20:27 |
| pubchem | ok | 2026-11-20 10:20:25 |
| missing (no r/tripreports posts mention it) | 2026-11-20 10:20:25 | |
| sider | ok | 2026-11-20 10:20:25 |
| structure | ok | 2026-11-20 10:20:25 |
| wikipedia | ok | 2026-11-20 10:20:25 |